DXCM
Price
$84.67
Change
-$0.67 (-0.79%)
Updated
May 9 closing price
Capitalization
53.47B
74 days until earnings call
INSP
Price
$151.25
Change
-$1.54 (-1.01%)
Updated
May 9 closing price
Capitalization
6.35B
86 days until earnings call
Ad is loading...

DXCM vs INSP

Header iconDXCM vs INSP Comparison
Open Charts DXCM vs INSPBanner chart's image
DexCom
Price$84.67
Change-$0.67 (-0.79%)
Volume$3.35M
Capitalization53.47B
Inspire Medical Systems
Price$151.25
Change-$1.54 (-1.01%)
Volume$309.47K
Capitalization6.35B
DXCM vs INSP Comparison Chart
Loading...
DXCM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DXCM vs. INSP commentary
May 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DXCM is a StrongBuy and INSP is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
May 11, 2025
Stock price -- (DXCM: $84.67 vs. INSP: $151.25)
Brand notoriety: DXCM and INSP are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: DXCM: 72% vs. INSP: 64%
Market capitalization -- DXCM: $53.47B vs. INSP: $6.35B
DXCM [@Medical Specialties] is valued at $53.47B. INSP’s [@Medical Specialties] market capitalization is $6.35B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DXCM’s FA Score shows that 0 FA rating(s) are green whileINSP’s FA Score has 0 green FA rating(s).

  • DXCM’s FA Score: 0 green, 5 red.
  • INSP’s FA Score: 0 green, 5 red.
According to our system of comparison, DXCM is a better buy in the long-term than INSP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DXCM’s TA Score shows that 6 TA indicator(s) are bullish while INSP’s TA Score has 3 bullish TA indicator(s).

  • DXCM’s TA Score: 6 bullish, 5 bearish.
  • INSP’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, DXCM is a better buy in the short-term than INSP.

Price Growth

DXCM (@Medical Specialties) experienced а +3.74% price change this week, while INSP (@Medical Specialties) price change was -5.36% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -1.49%. For the same industry, the average monthly price growth was +3.17%, and the average quarterly price growth was -3.96%.

Reported Earning Dates

DXCM is expected to report earnings on Jul 24, 2025.

INSP is expected to report earnings on Aug 05, 2025.

Industries' Descriptions

@Medical Specialties (-1.49% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DXCM($53.5B) has a higher market cap than INSP($6.35B). DXCM YTD gains are higher at: 8.872 vs. INSP (-18.411). DXCM has higher annual earnings (EBITDA): 917M vs. INSP (-17.06M). DXCM has more cash in the bank: 2.72B vs. INSP (460M). INSP has less debt than DXCM: INSP (24.8M) vs DXCM (2.59B). DXCM has higher revenues than INSP: DXCM (3.62B) vs INSP (625M).
DXCMINSPDXCM / INSP
Capitalization53.5B6.35B842%
EBITDA917M-17.06M-5,375%
Gain YTD8.872-18.411-48%
P/E Ratio106.11N/A-
Revenue3.62B625M580%
Total Cash2.72B460M592%
Total Debt2.59B24.8M10,460%
FUNDAMENTALS RATINGS
DXCM vs INSP: Fundamental Ratings
DXCM
INSP
OUTLOOK RATING
1..100
2261
VALUATION
overvalued / fair valued / undervalued
1..100
81
Overvalued
79
Overvalued
PROFIT vs RISK RATING
1..100
8665
SMR RATING
1..100
3574
PRICE GROWTH RATING
1..100
4160
P/E GROWTH RATING
1..100
79100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INSP's Valuation (79) in the Medical Specialties industry is in the same range as DXCM (81). This means that INSP’s stock grew similarly to DXCM’s over the last 12 months.

INSP's Profit vs Risk Rating (65) in the Medical Specialties industry is in the same range as DXCM (86). This means that INSP’s stock grew similarly to DXCM’s over the last 12 months.

DXCM's SMR Rating (35) in the Medical Specialties industry is somewhat better than the same rating for INSP (74). This means that DXCM’s stock grew somewhat faster than INSP’s over the last 12 months.

DXCM's Price Growth Rating (41) in the Medical Specialties industry is in the same range as INSP (60). This means that DXCM’s stock grew similarly to INSP’s over the last 12 months.

DXCM's P/E Growth Rating (79) in the Medical Specialties industry is in the same range as INSP (100). This means that DXCM’s stock grew similarly to INSP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DXCMINSP
RSI
ODDS (%)
Bearish Trend 2 days ago
74%
Bullish Trend 3 days ago
81%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
65%
Bearish Trend 2 days ago
72%
Momentum
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
77%
MACD
ODDS (%)
Bullish Trend 2 days ago
67%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
75%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 3 days ago
72%
Bullish Trend 16 days ago
87%
Declines
ODDS (%)
Bearish Trend 20 days ago
72%
Bearish Trend 2 days ago
73%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 2 days ago
65%
Aroon
ODDS (%)
Bullish Trend 2 days ago
70%
Bearish Trend 2 days ago
75%
View a ticker or compare two or three
Ad is loading...
DXCM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CSR61.380.83
+1.37%
Centerspace
NKSH26.140.01
+0.04%
National Bankshares
WLK80.00-0.44
-0.55%
Westlake Corp
RARE35.11-0.87
-2.42%
Ultragenyx Pharmaceutical
IBIO0.77-0.06
-6.83%
iBio

DXCM and

Correlation & Price change

A.I.dvisor indicates that over the last year, DXCM has been loosely correlated with CERS. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if DXCM jumps, then CERS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DXCM
1D Price
Change %
DXCM100%
-0.79%
CERS - DXCM
42%
Loosely correlated
-5.15%
PEN - DXCM
34%
Loosely correlated
+2.98%
IRMD - DXCM
34%
Loosely correlated
-1.54%
ACRS - DXCM
33%
Loosely correlated
-3.82%
COO - DXCM
32%
Poorly correlated
-0.78%
More